Forest Ray

6 days ago | 360dx.com | Forest Ray

NEW YORK – Natera is ramping up its R&D investments and expanding its commercial operations to take advantage of rising sales of its Signatera test for cancer recurrence and to solidify its presence in other fields such as genitourinary cancer.

1 week ago | genomeweb.com | Forest Ray

NEW YORK – Pharmaceutical giant Novo Nordisk sees an unconventional business opportunity in disease prevention and has teamed up with Genomics Ltd to focus on preventing obesity. The collaborators aim to identify people at higher risk for developing obesity, using a combination of polygenic risk scores (PRSs) and clinical factors, and to develop tailored solutions to help those individuals avoid growing obese.

1 week ago | 360dx.com | Forest Ray

NEW YORK – Myriad Genetics reported after the close of market Tuesday a year-over-year revenue loss of 3 percent for the first quarter of 2025, prompting the firm to lower its full-year financial guidance.

1 week ago | genomeweb.com | Forest Ray

NEW YORK – Myriad Genetics reported after the close of market Tuesday a year-over-year revenue loss of 3 percent for the first quarter of 2025, prompting the firm to lower its full-year financial guidance. The Salt Lake City-based genetic testing company finished the three months ending March 31 with $195.9 million in total revenue compared to $202.2 million for the same quarter in 2024.

1 week ago | genomeweb.com | Forest Ray

NEW YORK – Myriad Genetics reported after the close of market Tuesday a year-over-year revenue loss of 3 percent for the first quarter of 2025, prompting the firm to lower its full-year financial guidance. The Salt Lake City-based genetic testing company finished the three months ending March 31 with $195.9 million in total revenue compared to $202.2 million for the same quarter in 2024.